ZURICH (Reuters) – Contract drug manufacturer Lonza plans to double Swiss production capacity for Moderna’s COVID-19 vaccine, helping the U.S. drugmaker boost total output to as many as 3 billion doses in 2022. [L1N2ML2XZ]
(Reporting by John Miller; Editing by Riham Alkousaa)
